Polyclinic S. Orsola-Malpighi

Bologna 40138

2 studies enrolling now · 8 studies all time

What they study most

Advanced Solid Tumor, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound, Gynecologic Cancer, MDS, MF, Myelodysplastic Syndrome, Myelofibrosis, Post-ET Myelofibrosis, Post-PV MF, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis

Studies at this site

• Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure — Recruiting now
• Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib — Recruiting now
• A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis — Running, not enrolling
• Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. — Running, not enrolling
• Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF — Completed
• A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor — Paused
• Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA — Stopped early
• KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF — Status unconfirmed